Explore Stanford technologies available for licensing:

Researchers at Stanford have developed agents to enhance the therapeutic efficacy of a variety of anti-cancer therapeutics. Cell loss by apoptosis occurs in normal development and in tumor environments.

Disease Indication Oncology, hematological cancers, breast cancer, solid tumors

Drug Format Cell therapy

Drug Class Best-in-class

Target CD19, HER2, B7-H3, GPC2 and all other tumor antigens

Researchers at Stanford have developed methods to classify and treat MYC-driven hematopoietic cancers. The MYC oncogene drives the proliferation and survival of many hematopoietic cancers. These cancers are highly aggressive and do not respond to conventional chemotherapies.